{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:41:12Z","timestamp":1792442472323,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Vifor Fresenius Medical Care Renal Pharma Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"DOI":"10.1007\/s00467-026-07561-7","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:16:39Z","timestamp":1792394199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The pharmacokinetics of a single intravenous dose of difelikefalin in adolescents aged 12 to 17 years on hemodialysis"],"prefix":"10.1007","author":[{"given":"Chebl","family":"Mourani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrit","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline Abou","family":"Jaoudeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Enoiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"7561_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/ncpneph1040","volume":"5","author":"DR Kuypers","year":"2009","unstructured":"Kuypers DR (2009) Skin problems in chronic kidney disease. Nat Clin Pr Nephrol 5:157\u2013170. https:\/\/doi.org\/10.1038\/ncpneph1040","journal-title":"Nat Clin Pr Nephrol"},{"key":"7561_CR2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s40620-025-02221-9","volume":"38","author":"T Wang","year":"2025","unstructured":"Wang T, Goh JX, Seth S, Do LL, Tesfaye W, Sud K, Van C, Small F, Tarafdar S, Castelino RL (2025) Chronic kidney disease-associated pruritus and patient-centred outcomes: a systematic review. J Nephrol 38:371\u2013391. https:\/\/doi.org\/10.1007\/s40620-025-02221-9","journal-title":"J Nephrol"},{"key":"7561_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2025.101150","volume":"7","author":"E Kelepouris","year":"2025","unstructured":"Kelepouris E, Rhee CM (2025) CKD-associated pruritus: a patient-centered approach to reduce symptom burden. Kidney Med 7:101150. https:\/\/doi.org\/10.1016\/j.xkme.2025.101150","journal-title":"Kidney Med"},{"key":"7561_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.xkme.2020.08.011","volume":"3","author":"N Sukul","year":"2021","unstructured":"Sukul N, Karaboyas A, Csomor PA, Schaufler T, Wen W, Menzaghi F, Rayner HC, Hasegawa T, Al Salmi I, Al-Ghamdi SMG, Guebre-Egziabher F, Ure\u00f1a-Torres P-A, Pisoni RL (2021) Self-reported pruritus and clinical, dialysis-related, and patient-reported outcomes in hemodialysis patients. Kidney Med 3:42\u201353.e41. https:\/\/doi.org\/10.1016\/j.xkme.2020.08.011","journal-title":"Kidney Med"},{"key":"7561_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00467-023-05998-8","volume":"39","author":"S Shah","year":"2024","unstructured":"Shah S, Onugha E, Swartz SJ (2024) Chronic kidney disease-associated pruritus: what is known and its application in children. Pediatr Nephrol 39:25\u201335. https:\/\/doi.org\/10.1007\/s00467-023-05998-8","journal-title":"Pediatr Nephrol"},{"key":"7561_CR6","doi-asserted-by":"publisher","first-page":"938","DOI":"10.2340\/00015555-2454","volume":"96","author":"E Wojtowicz-Prus","year":"2016","unstructured":"Wojtowicz-Prus E, Kili\u015b-Pstrusi\u0144ska K, Reich A, Zachwieja K, Miklaszewska M, Szczepanska M, Szepietowski JC (2016) Chronic kidney disease-associated pruritus in children. Acta Derm Venereol 96:938\u2013942. https:\/\/doi.org\/10.2340\/00015555-2454","journal-title":"Acta Derm Venereol"},{"key":"7561_CR7","doi-asserted-by":"publisher","first-page":"c168","DOI":"10.1159\/000145461","volume":"109","author":"N Senturk","year":"2008","unstructured":"Senturk N, Ozkaya O, Aytekin S, Bek K, A\u00e7ikg\u00f6z Y, Aydin F, Bek Y, Turanli AY (2008) Characteristics of pruritus in children on peritoneal dialysis. Nephron Clin Pract 109:c168\u2013c172. https:\/\/doi.org\/10.1159\/000145461","journal-title":"Nephron Clin Pract"},{"key":"7561_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9970321","volume":"2021","author":"M Mehrkash","year":"2021","unstructured":"Mehrkash M, Golestaneh SJ, Madihi Y, Paknazar F, Hadian M, Akbari M, Abtahi-Naeini B (2021) Pruritus features in children with end-stage renal disease underwent dialysis: a cross-sectional study. Int J Pediatr 2021:9970321. https:\/\/doi.org\/10.1155\/2021\/9970321","journal-title":"Int J Pediatr"},{"key":"7561_CR9","unstructured":"WinHealth Pharma\u2019s licensed Difelikefalin injection significantly improves pruritus associated with chronic kidney disease in hemodialysis patients in Phase III clinical study in China (2024). https:\/\/www.winhealth.hk\/article\/384.html. Accessed 15 January, 2026"},{"key":"7561_CR10","unstructured":"European Medicines Agency Kapruvia (2024) Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kapruvia-epar-product-information_en.pdf. Accessed 1 December, 2025"},{"key":"7561_CR11","unstructured":"US Food and Drug Administration (2023) Korsuva (difelikefalin) injection, for intravenous use. Prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/214916s002lbl.pdf. Accessed 1 December, 2025"},{"key":"7561_CR12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1912770","volume":"382","author":"S Fishbane","year":"2020","unstructured":"Fishbane S, Jamal A, Munera C, Wen W, Menzaghi F (2020) A Phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med 382:222\u2013232. https:\/\/doi.org\/10.1056\/NEJMoa1912770","journal-title":"N Engl J Med"},{"key":"7561_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2022.100512","volume":"4","author":"J Topf","year":"2022","unstructured":"Topf J, Wooldridge T, McCafferty K, Sch\u00f6mig M, Csiky B, Zwiech R, Wen W, Bhaduri S, Munera C, Lin R, Jebara A, Cirulli J, Menzaghi F (2022) Efficacy of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis of KALM-1 and KALM-2 phase 3 studies. Kidney Med 4:100512. https:\/\/doi.org\/10.1016\/j.xkme.2022.100512","journal-title":"Kidney Med"},{"key":"7561_CR14","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1093\/ndt\/gfad245","volume":"39","author":"DE Weiner","year":"2024","unstructured":"Weiner DE, Schaufler T, McCafferty K, Kalantar-Zadeh K, Germain M, Ruessmann D, Morin I, Menzaghi F, Wen W, St\u00e4nder S (2024) Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis. Nephrol Dial Transpl 39:1125\u20131137. https:\/\/doi.org\/10.1093\/ndt\/gfad245","journal-title":"Nephrol Dial Transpl"},{"key":"7561_CR15","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s40262-023-01262-2","volume":"62","author":"JG Stark","year":"2023","unstructured":"Stark JG, Noonan PK, Spencer RH, Bhaduri S, O\u2019Connor SJ, Menzaghi F (2023) Pharmacokinetics, metabolism, and excretion of intravenous [14C]Difelikefalin in healthy subjects and subjects on hemodialysis. Clin Pharmacokinet 62:1231\u20131241. https:\/\/doi.org\/10.1007\/s40262-023-01262-2","journal-title":"Clin Pharmacokinet"},{"key":"7561_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12882-024-03790-w","volume":"25","author":"RH Spencer","year":"2024","unstructured":"Spencer RH, Noonan PK, Marbury T, Menzaghi F (2024) Impact of renal impairment on the pharmacokinetic profile of intravenous difelikefalin, a kappa opioid receptor agonist for the treatment of pruritus. BMC Nephrol 25:351. https:\/\/doi.org\/10.1186\/s12882-024-03790-w","journal-title":"BMC Nephrol"},{"key":"7561_CR17","unstructured":"US Food and Drug Administration Federal Regulation 21; Part 58: Good Laboratory Practice for Nonclinical Laboratory Studies (1978). https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-A\/part-58. Accessed 9 July, 2026"},{"key":"7561_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf297","volume":"18","author":"J Latus","year":"2025","unstructured":"Latus J, Mayer G, Narvaez C, Manu M, Jesus S, Ruessmann D, Manenti L (2025) Real-world safety of difelikefalin for chronic kidney disease-associated pruritus: initial insights from a European managed access programme. Clin Kidney J 18:sfaf297. https:\/\/doi.org\/10.1093\/ckj\/sfaf297","journal-title":"Clin Kidney J"},{"key":"7561_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2022.100513","volume":"4","author":"S Fishbane","year":"2022","unstructured":"Fishbane S, Wen W, Munera C, Lin R, Bagal S, McCafferty K, Menzaghi F, Goncalves J (2022) Safety and tolerability of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis from the phase 3 clinical trial program. Kidney Med 4:100513. https:\/\/doi.org\/10.1016\/j.xkme.2022.100513","journal-title":"Kidney Med"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07561-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07561-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07561-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:02:21Z","timestamp":1792440141000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07561-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":19,"alternative-id":["7561"],"URL":"https:\/\/doi.org\/10.1007\/s00467-026-07561-7","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"1 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was reviewed and approved by the Independent Ethics Committees of all participating institutions. All patients and their parents\/legal guardians, as required, provided written informed consent before being enrolled in the study. The study was conducted in compliance with the Declaration of Helsinki, the International Council for Harmonisation (ICH) E6 Guideline for Good Clinical Practice, Committee for Medicinal Products for Human Use (CHMP; EMA\/45110\/2007; EMA\/637844\/2022 [last update]) and the ethical considerations for clinical trials on medicinal products conducted with minors as amended, and in compliance with the EU Clinical Trial Directive (Directive 2001\/20\/EC).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants and their parents\/legal guardians, as required, provided written informed consent before being enrolled in the study. This included consent to the publication of the research results in an appropriate scientific journal.","order":2,"name":"Ethics","label":"Consent to participate and consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IM and ME are employees of CSL Vifor. CM, AK, PAJ and BR have no competing interests to declare.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}